Thermoresponsive Cysteamine Gel Eye Drops for Sustained Ocular Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cysteamine eye drops for treating corneal cystinosis are highly irritating, unstable, and require frequent administration, lasting only about one week when refrigerated, necessitating a more stable and less frequent dosing regimen.
Innovation Solution
A thermoresponsive gel-based ocular delivery system containing spray-dried cysteamine-loaded microparticles, primarily composed of biodegradable polymers like PLGA and PNIPAAm, which forms a gelled member upon administration, allowing sustained release of cysteamine for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cysteamine eye drops are used, then the treatment is simple to administer, but the stability is poor and dosing frequency must be high
Solution Approach 1:
The cysteamine drug is segmented into individual microparticles (200 nm to 10 μm diameter) embedded within the gel matrix, allowing controlled release while maintaining formulation stability. Each microparticle acts as an independent reservoir, improving overall formulation reliability without excessive complexity.
Solution Approach 2:
The invention uses a composite formulation combining thermoresponsive gel (PNIPAAm) with spray-dried microparticles containing cysteamine and biodegradable polymer. This composite structure provides both the stability of the polymer-encapsulated drug and the controlled release properties of the thermoresponsive gel, achieving enhanced reliability while managing formulation complexity.
2Duration of action of moving object
If conventional cysteamine eye drops are used, then the administration is frequent, but the duration of action is short
Solution Approach 1:
The cysteamine is pre-loaded into microparticles during manufacturing, creating a reservoir that releases drug over time. This preliminary encapsulation action extends the duration of action from hours to days, reducing dosing frequency from multiple times daily to potentially once weekly or less, while maintaining therapeutic efficacy.
Solution Approach 2:
The thermoresponsive gel undergoes a temperature-dependent phase transition that controls drug release parameters. At body temperature, the gel transitions from sol to gel state, modulating the release rate of cysteamine from microparticles. This parameter change enables sustained release over extended periods, increasing duration of action and decreasing dosing frequency.
3Object-affected harmful factors
If conventional cysteamine eye drops are used, then the formulation is simple, but the irritation to the eye is high
Solution Approach 1:
The biodegradable polymer and thermoresponsive gel act as intermediary materials between the cysteamine drug and the ocular tissue. These intermediaries control the release rate and buffer the direct contact between high-concentration cysteamine and the sensitive eye, significantly reducing irritation while maintaining therapeutic effectiveness. The complexity increase is justified by the substantial reduction in harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides a stable, less frequent dosing option for cysteamine, offering sustained release up to 30 times longer than conventional drops, enhancing patient compliance and reducing irritation by allowing self-administration and easy removal.
Implementation Method 1
a thermoresponsive gel may comprise poly(N-isopropyl acrylamide) (PNIPAAm)... which forms a gelled member upon administration
Implementation Method 2
removing at least a portion of the solvent from the droplets in the drying chamber, thereby forming a plurality of spray-dried microparticles
Data Source
AI summary
This document provided ocular delivery systems for treatment of cystinosis as well as methods for making such ocular delivery systems and methods for using such ocular delivery systems. For example, ocular delivery systems designed to include spray-dried, cysteamine-loaded microparticles suspended in a thermoresponsive gel are provided herein.